Zomedica CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Zomedica Corp. announced its Q2 2026 financial results, showing a significant increase in revenue driven by contract manufacturing and growth in key product lines, though gross profit margins experienced a slight decline.
Zomedica Corp. reported increased revenue for Q3 2025 and the nine months ended September 30, 2025, despite significant impairment charges totaling $55.8 million.
Zomedica Corp. reported increased revenue for Q2 2025, but a significant impairment charge in Q1 led to a higher net loss for the six-month period.
10-Q: Zomedica Corp. Reports Q1 2025 Results, Revenue Up Slightly Amidst Significant Impairment Charges
Zomedica Corp. saw a modest revenue increase in Q1 2025 but reported a substantial net loss due to significant impairment charges related to goodwill and intangible assets.
Zomedica Corp. saw a 10% increase in revenue year-over-year for Q3 2024, but reported a significant net loss due to impairment charges.
10-Q: Zomedica Corp. Reports Q2 2024 Results with Increased Revenue but Significant Impairment Charge
Zomedica Corp. saw a slight increase in revenue for Q2 2024, but reported a significant net loss due to a substantial goodwill impairment charge.
Zomedica Corp. saw a 14% increase in revenue in the first quarter of 2024 compared to the same period last year, but also experienced a larger net loss.